learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
Search
forLearn
5 / 26 resultslearn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn GT20029
research compound made to degrade androgen receptors in scalp
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn Follistatin
glycoprotein that inhibits TGF-β and promotes hair growth by antagonizing activin
Research
5 / 1000+ results
research Non-Clinical Safety Evaluation and Risk Assessment of Aleglitazar, a Dual PPAR α/γ Agonist, and Its Major Human Metabolite
Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
research Molecular Targeted Therapies for Cancer: Sorafenib Monotherapy and Its Combination with Other Therapies
Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.
research Cutaneous Gene Therapy
Cutaneous gene therapy could become a viable treatment for skin and hair disorders with improved vector development and gene expression control.
research The Histopathology of Noncicatricial Alopecia
Different types of hair loss have unique features under a microscope, but a doctor's exam is important for accurate diagnosis.
research Bendamustine in Indolent Non-Hodgkin's Lymphoma: A Practice Guide for Patient Management
Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.
Community Join
5 / 852 resultscommunity Amplifica and AMP-303 clinical phase 1
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
community Are there any news about scube3? Did they want to start the clinical trials soon?
The conversation is about skepticism regarding new hair loss treatments until they are FDA approved. People have been joking about treatments being 5-7 years away for decades.
community TRT. Pyrilutamide. Ru58841. Help
A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.
community Pyrilutamide binding affinity is similar to RU
Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.